donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > FGEN FibroGen > Key Indicators
FGEN FibroGen
11.570
-0.090-0.77%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-19.8% 105.2797 98.27% -1.3933 98.27% -1.3933 -8.26% 183.1894
Receivable Turnover(T)
58.89% 6.1049 58.34% 7.9384 58.34% 7.9384 73.79% 9.1175
Inventory Turnover(T)
-44.56% 0.4295 -28.52% 0.5414 -28.52% 0.5414 -29.81% 0.6013
Fixed Assets Turnover(T)
5.83% 2.9773 5.95% 2.566 5.95% 2.566 90.06% 2.955
Total Asset Rate(T)
42.31% 0.3362 40.42% 0.294 40.42% 0.294 144.09% 0.3414
ROIC
-113.59% -84.488% -101.1% -74.958% -101.1% -74.958% -12.7% -45.977%
ROE
-141.52% -106.407% -127.72% -91.878% -127.72% -91.878% -26.2% -55.201%
ROA
-61.95% -36.716% -61.21% -36.238% -61.21% -36.238% 3.76% -25.814%
Efficiency Ratios
ROE 5 Year Average
-- -- -38.22% -39.692% -- -- -- --
ROA 5 Year Average
-- -- -31.83% -19.147% -- -- -- --
Average 5 Years ROIC
-- -- -48.24% -33.589% -- -- -- --
Profitability Ratios TTM
Gross Margin
0.66% 94.681% -0.46% 94.530% -0.46% 94.530% 1.75% 95.644%
Operating Margin
-14.56% -109.076% -12.67% -122.617% -12.67% -122.617% 62.09% -74.458%
Net Margin
-13.79% -109.222% -14.81% -123.252% -14.81% -123.252% 60.57% -75.619%
EBITDA Margin
-26.11% -1.044% -24.7% -1.1632% -24.7% -1.1632% 60.2% -0.6819%
R & D Expense Ratio
8.72% 155.750% 14.66% 164.480% 14.66% 164.480% -36.24% 123.780%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
689.74% 54.381% 582.85% 42.448% 582.85% 42.448% 325.24% 28.080%
Total Assets to Common Equity
122.41% 471.967% 88.91% 369.991% 88.91% 369.991% 45.21% 261.060%
Debt to Asset Ratio
498.32% 61.327% 421.91% 47.686% 421.91% 47.686% 236.68% 31.409%
Current Ratio
-44.82% 2.0535 -54.57% 2.1023 -54.57% 2.1023 -56.04% 2.7394
Quick Ratio
-47.57% 1.8481 -57.22% 1.9095 -57.22% 1.9095 -58.01% 2.5339
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -71.69% 3.383% -- -- -- --
Revenue CAGR(5Y)
-- -- 1202.56% 5.555% -- -- -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
CEO: Conterno, Enrique A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...